Venus Remedies Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

Current Price and Market Context

As of 6 Feb 2026, Venus Remedies Ltd is trading at ₹764.00, marginally down by 0.24% from the previous close of ₹765.85. The stock’s intraday range has fluctuated between ₹751.00 and ₹775.00, reflecting moderate volatility. The 52-week high stands at ₹872.80, while the 52-week low is ₹277.85, underscoring the stock’s significant appreciation over the past year.

Technical Trend Evolution

The technical trend for Venus Remedies has softened from a strong bullish stance to a mildly bullish one. This subtle shift is indicative of a market recalibration, where momentum is still positive but tempered by emerging caution. The daily moving averages support this mildly bullish outlook, suggesting that short-term price action remains upward-biased, albeit with reduced conviction.

MACD Analysis: Divergent Weekly and Monthly Signals

The Moving Average Convergence Divergence (MACD) indicator presents a mixed scenario. On a weekly basis, the MACD is mildly bearish, signalling a potential short-term weakening in momentum. Conversely, the monthly MACD remains bullish, implying that the longer-term trend retains strength. This divergence suggests that while short-term traders might face some headwinds, the broader uptrend remains intact.

RSI Insights: Neutral Weekly, Bearish Monthly

The Relative Strength Index (RSI) on a weekly timeframe shows no definitive signal, hovering in a neutral zone that neither favours overbought nor oversold conditions. However, the monthly RSI is bearish, indicating that the stock may be experiencing some underlying selling pressure over the longer term. This bearish monthly RSI contrasts with the bullish monthly MACD, highlighting the importance of monitoring momentum shifts closely.

Bollinger Bands and Moving Averages: Mildly Bullish Signals

Bollinger Bands on both weekly and monthly charts are mildly bullish, suggesting that price volatility is contained within an upward trending channel. The daily moving averages reinforce this mildly bullish stance, with the stock price currently trading above key short-term averages. This technical alignment supports the view that Venus Remedies is maintaining upward momentum, though the pace may be moderating.

KST and Dow Theory Confirm Longer-Term Strength

The Know Sure Thing (KST) indicator and Dow Theory assessments both signal bullish trends on weekly and monthly timeframes. These indicators, which focus on momentum and trend confirmation respectively, provide reassurance that the stock’s longer-term trajectory remains positive despite short-term fluctuations.

On-Balance Volume (OBV) Shows No Clear Trend

Volume-based analysis via OBV reveals no discernible trend on either weekly or monthly charts. This lack of volume confirmation suggests that recent price movements may not be strongly supported by trading activity, a factor that could contribute to the observed technical caution.

Comparative Returns: Venus Remedies vs Sensex

Venus Remedies has delivered exceptional returns relative to the benchmark Sensex over multiple time horizons. Over the past year, the stock has surged by 119.16%, vastly outperforming the Sensex’s 6.44% gain. Longer-term performance is even more striking, with 3-year returns at 402.63% versus 36.94% for the Sensex, and a 10-year return of 606.75% compared to 238.44% for the benchmark. These figures underscore the company’s robust growth trajectory and resilience in the pharmaceuticals sector.

Mojo Score and Rating Update

Venus Remedies currently holds a Mojo Score of 74.0, reflecting a solid technical and fundamental standing. The Mojo Grade has been revised from a Strong Buy to a Buy as of 1 Feb 2026, signalling a slight moderation in conviction but maintaining a positive outlook. The Market Cap Grade is rated 4, indicating a mid-sized market capitalisation with growth potential. This recalibration aligns with the observed technical trend shift and mixed indicator signals.

Sector and Industry Context

Operating within the Pharmaceuticals & Biotechnology sector, Venus Remedies benefits from favourable industry tailwinds including rising healthcare demand and innovation in drug development. The sector’s overall momentum remains constructive, supported by robust fundamentals and increasing investor interest. Venus Remedies’ technical profile, while showing some short-term caution, remains consistent with the sector’s broader positive trajectory.

Investor Implications and Outlook

For investors, the mildly bullish technical trend combined with mixed indicator signals suggests a cautious but optimistic stance. The divergence between weekly and monthly MACD and RSI readings highlights the importance of monitoring short-term price action closely while maintaining confidence in the longer-term uptrend. The absence of strong volume confirmation via OBV warrants prudence, as sustained momentum will likely require increased trading activity.

Given the stock’s impressive multi-year returns and solid sector fundamentals, Venus Remedies remains an attractive proposition for investors with a medium to long-term horizon. However, the recent downgrade from Strong Buy to Buy and the subtle technical shifts imply that entry points should be carefully evaluated, ideally on dips or consolidation phases.

Summary

Venus Remedies Ltd’s technical landscape is characterised by a transition to a mildly bullish trend, supported by daily moving averages and longer-term bullish KST and Dow Theory signals. Mixed readings from MACD and RSI across weekly and monthly timeframes introduce a degree of caution, while Bollinger Bands suggest contained volatility within an upward channel. The lack of volume trend confirmation via OBV and the recent Mojo Grade downgrade from Strong Buy to Buy further temper enthusiasm.

Nonetheless, the company’s stellar long-term returns relative to the Sensex and its solid sector positioning underpin a fundamentally sound investment case. Investors should weigh the current technical nuances carefully, balancing short-term caution with longer-term growth prospects in the Pharmaceuticals & Biotechnology sector.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →